Percentage of application of first and only doses by age group against SARS-CoV-2 in Colombia
DOI:
https://doi.org/10.33975/riuq.vol35nS1.816Keywords:
COVID-19, SARS-CoV-2, pandemic, vaccinesAbstract
Introduction: The return of COVID-19 in high-income countries with developed vaccine programs has raised concerns about the durability of the vaccine's efficacy, mainly against the more transmissible delta and omicron variant. Objective: to show the progress of the application of the first and only doses by age group for vaccination against SARS-COV-2 in Colombia, between the period from February 17 to November 30, 2021. Methodology: This research is carried out under a cross-sectional study, as a source of information it was obtained from the national vaccination plan against COVID-19 from the website of the Ministry of Health and Social Protection. Results: It was deduced that the age groups with the highest percentages of application of first and only doses were: 75-79 years with 100.1%, 80-100 years with 99.3%, and 45-49 years with 97. 3%. And the age groups with the lowest percentages of application of first and only doses have: 3-4 years with 22.7%, 5-9 years with 32%, and 10-11 years with 41.0%. Conclusion: The population's expectations in the acceptance of immunobiologicals against COVID-19 are beneficial and show a high level of trust towards government authorities. In addition, there is a good tendency of the participants to comply with the immunization schedule.
Downloads
References
Scott, J Richterman, A. Cevik, M. (2021). Vacunación Covid-19: se exagera la evidencia de la disminución de la inmunidad. DOI: doi.org/10.1136/bmj.n2320
Polack FP, Thomas SJ, Kitchin N, etalC4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med 2020; 383:2603-15. doi: 10.1056/NEJMoa2034577 pmid: 33301246
Baden LR, El Sahly HM, Essink B, etalCOVE Study Group. Efficacy and safety of the mRNA1273 SARS-CoV-2 vaccine. N Engl J Med 2021; 384:403-16. doi: 10.1056/NEJMoa2035389 pmid: 33378609
Voysey M, Clemens SAC, Madhi SA, etalOxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021; 397:99-111. doi: 10.1016/S0140-6736(20)32661-1 pmid: 33306989
Sadoff J, Gray G, Vandebosch A, etalENSEMBLE Study Group. Safety and efficacy of singledose Ad26.COV2. S vaccine against covid-19. N Engl J Med 2021; 384:2187-201. doi: 10.1056/NEJMoa2101544 pmid: 33882225
Tregoning JS, Flight KE, Higham SL, Wang Z, Pierce BF. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness, and escape. Nat Rev Immunol 2021:1-11. doi: 10.1038/s41577-021-00592-1. pmid: 34373623
Cevik M, Grubaugh ND, Iwasaki A, Openshaw P. COVID-19 vaccines: Keeping pace with SARSCoV-2 variants. Cell 2021: S0092-8674(21)01057-6. doi: 0.1016/j.cell.2021.09.010. pmid: 34534444
Richterman A, Meyerowitz EA, Cevik M. Indirect protection by reducing transmission: ending the pandemic with SARS-CoV-2 vaccination. Open Forum Infect Dis 2021. doi: 10.1093/ofid/ofab259
Díaz Pinzón, J. E. (2020a). Descripción estadística del COVID- 19 según el grupo etario en Colombia. Revista Repertorio De Medicina Y Cirugía, 79–85. https://doi.org/10.31260/RepertMedCir.01217372.1098
Díaz Pinzón, J. E. (2020a). Continuidad con los procesos pedagógicos de los estudiantes durante la pandemia ocasionada por el COVID-19. Revista Repertorio De Medicina Y Cirugía, 108–112. Recuperado a partir de https://revistas.fucsalud.edu.co/index.php/repertorio/article/view/1128
Díaz Pinzón, J. E. (2020c). Positividad y proporción para muestras por COVID-19 en Colombia. Revista Repertorio De Medicina Y Cirugía, 127–130. https://doi.org/10.31260/RepertMedCir.01217372.1134
Instituto Nacional de Salud. Coronavirus (COVID-19) en Colombia. [Internet]. 2022 disponible en: https://www.ins.gov.co/Paginas/Inicio.aspx
Alencastro Vaca, C. J., & Jiménez Peralta, A. L. (2022). Perspectivas poblacionales en la aceptación de los inmunobiológicos contra covid-19: aceptación de los inmunobiológicos contra covid-19. UNESUM-Ciencias. Revista Científica Multidisciplinaria. ISSN 2602-8166, 6(1), 31-40. https://doi.org/10.47230/unesum-ciencias.v6.n1.2022.613
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Revista de Investigaciones Universidad del Quindío
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
